SLXN Silexion Therapeutics: Earnings per share for the last 12 months

Silexion (SLXN) - corporate logo

The prospects of Silexion Therapeutics Corp (SLXN) depend on the outcomes of RNA drug trials, which necessitates strict capital management. The company plans to generate revenue from pancreatic cancer therapy via siRNA technologies. The YoY change in EPS on a rolling 12-month basis helps determine the real value of assets, where the current figure is 37.10. The success of a single molecule would ensure global reach and colossal profits with minimal expenditures.

Silexion (SLXN) Earnings per share for the last twelve months: for the period 11/23/2025 - 11/18/2026

SLXN (Silexion): analytical breakdowns and indicator data

- company stock capitalization data:
Fundamental company valuation:SLXN Silexion Therapeutics Corp
Flagship merchandise of Silexion Therapeutics Corp.

This indicator measures the dynamics of net earnings per share over a rolling year, reflecting the market's revaluation of business profitability. By analyzing the 12-month YoY earnings per share growth rate, an investor assesses the efficiency of corporate income capitalization. For Silexion Therapeutics Corp (SLXN), this metric is critical, as oncology RNA therapy is currently in the clinical testing stage. The future sustainability of the company depends directly on the commercialization of its platforms. High volatility on the chart underscores the risks associated with early-stage development.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year APRE (aprea.com)|KZIA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months